Table 1 Role of lncRNAs in regulation of PI3K/AKT, MAPK, and TGF-β signaling pathways in breast tumor cells
Study | Year | LncRNA | Target | Samples | Function | Clinical application |
|---|---|---|---|---|---|---|
TU [32] | 2022 | LINC01133 | PRR5/AKT | MDA-MB-231, MDA-MB-468, and Hs578T cell lines Xenograft model | Oncogene | Diagnosis |
SADEGHALVAD [36] | 2022 | HOTAIR | PI3K/AKT | MCF-7 cell line | Oncogene | Diagnosis |
LI [40] | 2019 | HOTAIR | PI3K/AKT | MCF-7 and SKBR3 cell lines | Oncogene | Diagnosis |
HE [41] | 2022 | KB-1980E6.3 | PI3K/AKT | 51T 51N* BT-549, MDA-MB-231, SKBR3, MDA-MB-468 and MCF-7 cell lines Xenograft model | Oncogene | Diagnosis and prognosis |
HAN [42] | 2019 | GHET1 | c-Myc and PI3K/AKT pathways | 30T 30N MCF-7 cell line Xenograft model | Oncogene | Diagnosis |
NONG [46] | 2021 | FOXD2-AS1 | PI3K/AKT | 60T 60N MCF-7 cell line | Oncogene | Diagnosis |
SHENG [47] | 2020 | SOX21-AS1 | PI3K/AKT | 88T 88N MCF-7, BT-20, MDA-MB-231, and MCF-10A cell lines Xenograft model | Oncogene | Diagnosis and prognosis |
FANG [49] | 2022 | MBNL1-AS1 | miR-423-5p/CREBZF | 60T 60N MCF-10A, BT474, MDA-MB-231, MDA-MB-453, ZR-75–30, and MCF-7 cells lines Xenograft model | Tumor suppressor | Diagnosis and prognosis |
ZHANG [51] | 2020 | ZFAS1 | miR-589/PTEN | MCF-10A, T47D, MCF-7, MDA-MB-435 and BT-549 cell lines | Tumor suppressor | Diagnosis |
GAO [52] | 2019 | PTENP1 | miR-20a/PTEN | 52T 52N MDA-MB-231, T-47D and MCF-7 cell lines Xenograft model | Tumor suppressor | Diagnosis and prognosis |
SHI [55] | 2018 | PTENP1 | miR-19/PTEN/PI3K/Akt | 20T 20N MCF-7 and MDA-MB-231 cell lines | Tumor suppressor | Diagnosis |
LEI [56] | 2022 | DUXAP8 | PI3K/AKT and EZH2 | 50T 50N MCF-12A, MCF-12 F, MCF-7, T47D, ZR-75–1, HCC-1806, MDA-MB-468, BT-549, and MDA-MB-231 cell lines Xenograft model | Oncogene | Diagnosis and prognosis |
WANG [59] | 2021 | SNHG6 | miR-543/LAMC1 | 28T 28N MCF-7, SK-BR-3, MDAMB-231, and BT-549 cell lines Xenograft model | Oncogene | Diagnosis |
LI [60] | 2019 | UCA1 | EZH2 and AKT | 10 ER + 10 ER- MCF-7, T47D, LCC2, and LCC9 cell lines | Oncogene | Diagnosis |
FANG [61] | 2022 | TTN-AS1 | miR-107/ZNRF2 | MCF-7 cell line | Oncogene | Diagnosis |
ZHOU [74] | 2022 | HULC | IGF1R | MCF7 and MDA-MB-231 cell lines Xenograft model | Oncogene | Diagnosis |
ZHANG [75] | 2021 | IGF2-AS | IGF2 | 95T 95N MCF-7, SK-BR-3, T47D, and MDA-MB-231 cell lines Xenograft model | Tumor suppressor | Diagnosis and prognosis |
LI [76] | 2018 | GAS5 | miRNA-196a-5p/FOXO1 | 103T 50N MDA-MB-231 and MDA-MB-468 cell lines | Tumor suppressor | Diagnosis and prognosis |
ZHANG [77] | 2019 | ZEB2‐AS1 | ZEB2 | 98T 98N MCF‐10A, T47D, MDA‐MB‐435, MCF‐7, and MDA‐MB‐23 cell lines Xenograft model | Oncogene | Diagnosis and prognosis |
LIN [81] | 2020 | BDNF-AS | RNH1/TRIM21 | 162T 162N MCF-7R and MDA-MB-231 cell lines Xenograft model | Oncogene | Diagnosis and prognosis |
CHEN [84] | 2019 | HOTAIR | PTEN | SK-BR-3 cell line Xenograft model | Oncogene | Diagnosis |
CHEN [88] | 2020 | Linc00839 | PI3K/AKT | 837T 105N (TCGA) 32T 32N MCF‐7, BT549 and MDA‐MB‐231 cell lines Xenograft model | Oncogene | Diagnosis and prognosis |
ZHONG [90] | 2021 | AC012213.3 | RAD54B | 1109T 113N (TCGA) 11T 11N MCF-7, T47D, MDA-MB-231 and MDA-MB-469 cell lines | Oncogene | Diagnosis and prognosis |
TAO [92] | 2020 | SCAMP1-TV2 | PUM2 | 20T 20N MCF-10A, MCF-7, and MDA-MB-231 cell lines Xenograft model | Oncogene | Diagnosis |
WANG [100] | 2021 | ARHGAP5-AS1 | SMAD7 | 1109T 113N (TCGA) MDA-MB-231 and LM2 cells, SKBR3 and BT549 cell lines | Tumor suppressor | Diagnosis |
WU [101] | 2017 | CCAT2 | TGF-β | 60T 60N LCC9, MDA-MB_231 and MCF-7 cell lines | Oncogene | Diagnosis |
HOU [102] | 2018 | Linc-ROR | TGF-β | 94T 94N MDA-MB-231 and MCF-7 cell lines Xenograft model | Oncogene | Diagnosis and prognosis |
LI [103] | 2021 | HNF1A-AS1 | miR-363/SERTAD3 | 82T 82N MCF-7, BT549, ZR-75–30, MDA-MB-231, HCC1937 and MDA-MB-436 cell lines Xenograft model | Oncogene | Diagnosis and prognosis |
DONG [105] | 2021 | LINC00052 | miR-145-5p/TGFBR2 | 45T 45N MDA-MB-231, MDA-MB-468, T47D, SKBR3 and MCF-7 cell lines | Oncogene | Diagnosis |
ZHANG [106] | 2019 | CASC2 | TGF-β | 52T 52N LCC9, MDA-MB-231, and MCF-7 cell lines | Tumor suppressor | Diagnosis |
LI [118] | 2017 | ANCR | RUNX2 | 25T 25N MCF7, T47D, MDA-MB-231, MDA-MB-231HM and BT549 cell lines Xenograft model | Tumor suppressor | Diagnosis |
LI [119] | 2021 | TPA | TGF-β | MCF-7 cell line Xenograft model | Oncogene | Diagnosis |
ZHOU [121] | 2019 | lncRNA-NORAD | TGF-β | 21T 10N MDA-MB231 and MCF-7 cell lines Xenograft model | Oncogene | Diagnosis and prognosis |
LI [127] | 2018 | AC026904.1 and UCA1 | Slug | 60T 60N MDA-MB-231 and luc-D3H2LN cell lines Xenograft model | Oncogene | Diagnosis and prognosis |
REN [135] | 2018 | HOTAIR | H3K27 | 39T(invasive) 20T (in situ) MDA-MB-231 and MCF-7 cell lines Xenograft model | Oncogene | Diagnosis and prognosis |
TANG [138] | 2020 | DCST1-AS1 | ANXA1 | MDA-MB-231, BT-549, T-47D, and MCF7 cell lines | Oncogene | Diagnosis |
FANG [140] | 2017 | HOXA-AS2 | miR-520c-3p/ TGFBR2/RELA | 38T 38N MDA-MB-231, MDA-MB-453, and MCF-7 cell lines Xenograft model | Oncogene | Diagnosis and prognosis |
NI [146] | 2021 | ADAMTS9-AS2 | RPL22 | 62T 62N MDA-MB-231 and HCC1937 cell lines Xenograft model | Tumor suppressor | Diagnosis and prognosis |
ZHOU [152] | 2022 | TGFB2-AS1 | SMARCA4 | 281T 281N MDA-MB-231, SUM159PT and BT-549 cell lines Xenograft model | Tumor suppressor | Diagnosis and prognosis |
ZHANG [161] | 2021 | CBR3-AS1 | miR-25-3p/MEK4/JNK1 | 96T 96N MCF-7, T47D, MDA-MB-231 and HEK-293 T cell lines Xenograft model | Oncogene | Diagnosis and prognosis |
CHEN [162] | 2017 | PTENP1 | AKT and MAPK | MCF7 and 293T cell lines | Tumor suppressor | Diagnosis |
LU [163] | 2018 | lncCAMTA1 | miR-20b/VEGF | MDA-MB-231 cell line | Oncogene | Diagnosis |
OUYANG [164] | 2021 | PRNCR1 | miR-377/CCND2 | 64T 64N MDA-MB-231, MCF-7, BT-549, MDAMB-468 and SK-BR-3 cell lines | Oncogene | Diagnosis and prognosis |
PENG [167] | 2017 | Linc- ROR | DUSP7 | MCF-7 cell line | Oncogene | Diagnosis |
CHEN [172] | 2020 | MIR100HG | miR-5590-3p/OTX1 | 20T 20N MDA-MB-231, MDA-MB-453, MDA-MB-468 and MDA-MB-415 cell lines Xenograft model | Oncogene | Diagnosis |
ZENG [184] | 2022 | SNHG5 | IGF2BP2 | 30T 30N Xenograft model | Oncogene | Diagnosis |